CEACAM5 and colorectal carcinoma: As far as we know, there have been no studies assessing serum levels of CXCL1 and CXCR1 in CRC patients in relation to the clinicopathological features of the tumor or evaluating the prognostic and diagnostic utility of CXCL1 and CXCR1 in comparison to the well-established classical tumor biomarker (CEA) and the indicator of the inflammatory process (CRP).